126 related articles for article (PubMed ID: 12632928)
1. [Mechanism of multidrug resistance of ovarian cancer].
Miedzińska-Maciejewska M; Wcisło G
Przegl Lek; 2002; 59(10):854-8. PubMed ID: 12632928
[TBL] [Abstract][Full Text] [Related]
2. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
3. [Multidrug resistance--genes and chemotherapy of ovarian cancer].
Leng J; Liang J
Zhonghua Yi Xue Za Zhi; 1995 Sep; 75(9):567-9. PubMed ID: 8556550
[No Abstract] [Full Text] [Related]
4. Advances in the management of epithelial ovarian cancer.
Berkenblit A; Cannistra SA
J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567
[TBL] [Abstract][Full Text] [Related]
5. The epigenetics of ovarian cancer drug resistance and resensitization.
Balch C; Huang TH; Brown R; Nephew KP
Am J Obstet Gynecol; 2004 Nov; 191(5):1552-72. PubMed ID: 15547525
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the management of women with ovarian cancer.
Eltabbakh GH
Minerva Ginecol; 2004 Feb; 56(1):81-9. PubMed ID: 14973412
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic factors in ovarian epithelial cancer].
Nishida T
Gan To Kagaku Ryoho; 1996 May; 23(6):805-9. PubMed ID: 8645035
[TBL] [Abstract][Full Text] [Related]
8. Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity.
Saldivar JS; Wu X; Follen M; Gershenson D
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S56-71. PubMed ID: 17884153
[TBL] [Abstract][Full Text] [Related]
9. Complete remission of platinium refractory ovarian cancer with second line tegafur with uracil monotherapy: a case report.
Camci C; Sevinc A; Aslan Y; Kalender ME; Buyukberber S
Cancer Chemother Pharmacol; 2009 Mar; 63(4):745-8. PubMed ID: 18504578
[TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
Yakirevich E; Sabo E; Naroditsky I; Sova Y; Lavie O; Resnick MB
Gynecol Oncol; 2006 Jan; 100(1):152-9. PubMed ID: 16198399
[TBL] [Abstract][Full Text] [Related]
11. Reversal of multidrug resistance by small interfering double-stranded RNAs in ovarian cancer cells.
Zhang T; Guan M; Jin HY; Lu Y
Gynecol Oncol; 2005 May; 97(2):501-7. PubMed ID: 15863151
[TBL] [Abstract][Full Text] [Related]
12. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.
Mozzetti S; Ferlini C; Concolino P; Filippetti F; Raspaglio G; Prislei S; Gallo D; Martinelli E; Ranelletti FO; Ferrandina G; Scambia G
Clin Cancer Res; 2005 Jan; 11(1):298-305. PubMed ID: 15671559
[TBL] [Abstract][Full Text] [Related]
13. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
Eitan R; Kushnir M; Lithwick-Yanai G; David MB; Hoshen M; Glezerman M; Hod M; Sabah G; Rosenwald S; Levavi H
Gynecol Oncol; 2009 Aug; 114(2):253-9. PubMed ID: 19446316
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and management of epithelial ovarian cancer.
Bhoola S; Hoskins WJ
Obstet Gynecol; 2006 Jun; 107(6):1399-410. PubMed ID: 16738170
[TBL] [Abstract][Full Text] [Related]
15. Potential predictors of chemotherapy response in ovarian cancer--how do we define chemosensitivity?
O'Toole SA; Sheppard BL; Laios A; O'Leary JJ; McGuinness EP; D'Arcy T; Bonnar J
Gynecol Oncol; 2007 Feb; 104(2):345-51. PubMed ID: 17027070
[TBL] [Abstract][Full Text] [Related]
16. [Chemoresistance in ovarian cancer. State of the art and future prospects].
Katsaros D; Fracchioli S; Arese P; Enria R; Cassinelli P; Mingrone K; Piccinno R; Rigault de la Longrais IA; Massobrio M
Minerva Ginecol; 1999 Dec; 51(12):483-99. PubMed ID: 10767997
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.
Chen YJ; Yuan CC; Chow KC; Wang PH; Lai CR; Yen MS; Wang LS
Gynecol Oncol; 2005 Apr; 97(1):110-7. PubMed ID: 15790446
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors.
L'Espérance S; Popa I; Bachvarova M; Plante M; Patten N; Wu L; Têtu B; Bachvarov D
Int J Oncol; 2006 Jul; 29(1):5-24. PubMed ID: 16773180
[TBL] [Abstract][Full Text] [Related]
19. Ovarian cancer: strategies for overcoming resistance to chemotherapy.
Agarwal R; Kaye SB
Nat Rev Cancer; 2003 Jul; 3(7):502-16. PubMed ID: 12835670
[TBL] [Abstract][Full Text] [Related]
20. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.
Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Aghajanian C; Barakat RR; Chi DS
Gynecol Oncol; 2008 Feb; 108(2):276-81. PubMed ID: 18063020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
